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Abstract 
Background: Urinary tract infection (UTI) is one of the most common 
bacterial infections. The most common cause is Escherichia coli. This 
research is done with the aim at compare effect of ciprofloxacin with 
nalidixic acid in the infection of different parts of the urinary tract. 
Methods: In this cross-sectional study, 130 patients with symptoms of 
the urinary tract infection referred to Imam Hossain Hospital of 
Shahrood were studied. For the all patients, urine samples were 
collected by standard method and urine analysis and culture was 
performed. Then, positive culture samples were tested by antibiogram 
and the resistance rate for the two antibiotics ciprofloxacin and 
nalidixic acid and MBC and MIC was investigated. 
Results: Of the 130 patients with symptoms of UTI (fever, flank pain or 
tenderness and dysuria, urgency or frequency (84 patients had positive 
urine culture. Of all patients with positive urine, 31 cases had 
symptoms of pyelonephritis, 25 patients had symptoms of cystitis and 
28 patients had symptoms of UTI. In antibiogram for positive urine 
samples, 21 pieces were resistant to ciprofloxacin and 46 pieces were 
resistant to nalidixic acid which significantly reduced resistance to 
ciprofloxacin (P=0.005). There was no significant difference between 
the two antibiotics in place of clinical symptoms and drug resistance. 
So there was no significant difference between the two MIC and MBC 
in place of clinical symptoms and drug resistance. 
Conclusions: This study showed that ciprofloxacin is more effective in 
controlling infection of different parts of the urinary tract due to less 
drug resistance. 
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Introduction 
Urinary tract infections (UTI) are a generic term for the 
replacement and growth of a pathogen in the kidney, bladder, 
and urethra. The prevalence of urinary tract infection in boys is 
more common the girls than in the first year of life, and after 
one year, the prevalence of girls is significantly higher.1-2 The 
reason for such a distribution of age and sex can be attributed 
to the shortness of the urethra in the female genome, which 
makes it easier for the microbe to go into the urinary tract.3 The 
most important symptoms of the disease are including pain, 
hematuria, dysuria, urinary incontinence, pain in the lower 
back, fever and abdominal pain.3-4 Several organisms interfere 
with the development of urinary tract infections, the most 
common of which is E. coli. Over 80% are caused by E- coli, a 
Gram negative bacillus. Other causes of urinary tract infection 
include Enterobacter agglomerans, Proteus mirabilis, Klebsiella 
pneumonia, Pseudomonas aeruginosa, Staphylococcus 
saprophyticus and Enterococcus faecalis.5-6 E. coli is a large 
heterogeneous group of gram-negative bacilli in the form of a 
bar without spores, a part of the natural flora of the intestine. 
This bacterium is a natural habitat for humans and animals, but 
if it enters other devices in different ways, it will cause 
infection.7-9 Treatment for mild infections is often out-patient 
and with oral antibiotics but in severe cases, especially in 
pyelonephritis, treatment is administered as an adjunct to an 
antibiotic.10 Appropriate antibiotic selection depends on several 
factors such as the outcome of urine culture and its 
antibiogram, the age of the patient and the presence of 
accompanying illnesses. One of the problems of treatment is 
the antibiotic-resistant strains.11-12 This problem occurs as a 
defensive reaction by infectious agents and from the very 
beginning, the discovery of antibiotics has also existed.11 It is 
also a matter of accelerating and intensifying the process of 
resistance to mankind and preventing the current self-made 
process to reduce the occurrence of resistance and control.12 
Factors such as inappropriate diagnosis of illnesses, the supply 
of counterfeit drugs to the pharmaceutical market, the 
administration of inappropriate drugs, or inappropriate dosage, 
inadequate training and the problem of hospital infections all 
work together and increase drug resistance.13 Ciprofloxacin and 
nalidixic acid are increasingly used in the treatment of urinary 
tract infections but the drug resistance level is not clear.14-15 
The procedure for performing antibiotics is based on the MIC 
(The lowest amount of antibiotics that can significantly inhibit 
the growth of an organism after a specific incubation period) 
and MAC (The lowest concentration of antibiotics, which can 
reduce the bacterial population by 1000 times after 24 hours) 
criteria, which, according to the American National Laboratory 
Standards Committee (NCCLS), is a gold standard for 
determining antimicrobial susceptibility and resistance.16 Also, 
since conventional antibiogram methods based on disk have 
many problems (lack of reliability and more human error) and 
quality we decided to test antibiotic ciprofloxacin and nalidixic 
Acid antibodies against E. coli based on the precise MIC and 
MBC methods.16-18 Furthermore, the resistance rates of urinary 
E. coli to various antimicrobials show large inter-country 
variability. Only a few studies have shown that E. coli 
resistance rates differ for hospital-acquired and community-
acquired UTI.9-11 Measuring and comparing the levels of AMR 
in both hospital- and community-acquired UTI is essential 
because although effects of AMR are mainly felt in healthcare 
facilities, the greatest use of antimicrobials occurs in the 
community.19 The prevalence of AMR including hospital and 
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community urinary E. coli resistance levels is not completely 
known in Iran. Obtaining this information is important because 
it not only provides knowledge about the health status of a 
population, but also contributes to disease management 
decisions.13 This study was done with the aim of compare effect 
of ciprofloxacin with nalidixic acid in the infection of different 
parts of the urinary tract. 
Materials and Methods  
This is a cross-sectional study with the aim of comparing 
the effectiveness and resistance rate of two antibiotics 
ciprofloxacin and nalidixic acid on UTI. In this study, 130 
patients admitted to Imam Hossain Hospital of Shahroud with 
the diagnosis of clinical signs of UTI (upper urinary tract 
including: fever, flank pain or tenderness and lower urinary 
tract including dysuria, urgency or frequency), during (March 
2015 to February 2016) were selected by convenient method. 
The initial selection of these patients was based on the positive 
urine culture test. Then a researcher-made questionnaire 
containing demographic and clinical data was completed by 
patients. 
Inclusion criteria: having urinary tract infection 
(pyelonephritis, cystitis and urethritis) and satisfaction of 
entering the research. 
Exclusion criteria, if there was: a history of allergy to 
nalidixic acid; evidence of renal dysfunction (serum creatinine 
greater than 130 μmol/L); a history of renal calculi (these 
patients are known to relapse); or pregnancy. In addition, 
patients known to be infected with organisms resistant to the 
study drug or who had antimicrobial therapy less than 72 h 
before entry were excluded. 
The urine sample was taken by the Middle Stream method 
and sent to the laboratory of Imam Hossain Hospital for urine 
culture (significant bacteriuria was defined as a midstream 
urine culture bacterial count of greater than or equal to 105 
colony forming units (cfu)/L of urine) and antibiogram tests in 
EMB and Blood Agar selective environments.13-15 In the next 
step, colonies grown on the EMB medium were examined for 
Enterobacteriaceae type. To do this, the oxidase test was first 
performed and if the oxidase test was negative, a differential 
diagnosis of lactose fermentation was performed and a final 
diagnosis was made.20 
Determination of antibiotic susceptibility by Disk Agar 
diffusion (DAD): According to the Clinical and Laboratory 
Standards Institute (CLSI) instruction,21 after removing all 
specimens from the freezer -20° C and their culture at Muller 
Hinton Agar (3 times), pure bacterial colonies were harvested 
and the turbidity of 0.5 McFarland was obtained in bacterial 
serum physiology. Then, a bacterial suspension was inoculated 
into a Muller Hinton Agar medium (in three different 
directions) and after a few minutes (to absorb the humidity of 
the environment), antibiotic discs were placed in the 
environment and then they were incubated at 35 ° C. The 
inhibition zone for all antibiotics was measured after 20 to 16 
hours. 
MIC (Minimum Inhibitory Concentration): based on the 
CLSI instruction recommendation, antibiotic stoiches were 
prepared as 10X in the highest concentration.22 The following 
formula was used to prepare the antibiotic suitable for 
preparation of antibiotic stokes. After obtaining the appropriate 
amounts of antibiotics in milligrams, each antibiotic was 
dissolved in its proper solvent and reached the appropriate 
volume. Finally, of Micro Broth Dilution method was used to 
determine the MIC level of antibiotics. In order to determine 
the MBC (Minimum bacterial Concentration), 10 μl of wells 
that were free from turbidity were removed and cultured on the 
surface of the Muller Hinton Agar and after 18-24 hours 
incubation at 37 ° C was investigated. The amount of MBC 
was determined based on the minimum concentration of drug 
that has a fungal effect on the bacteria. Data were analyzed 
using SPSS software.    
This study has an ethics code number 
(IR.SHMU.REC.1394.66) from research deputy of Shahroud 
University of Medical Sciences. The essential information and 
the objectives of the study were explained to the patients and 
written consent was obtained for participation in the plan. 
Results 
Of the 130 patients with symptoms of UTI, 84 patients 
(64.6%) had positive urine culture. Among the positive samples 
of urine culture, 78 cases (92.9%) were E. coli. Three cases 
(3.6%) were coagulase-negative Staphylococci, two cases 
(2.4%) were E. agglomerans and one case (1.2%) was K. 
pneumonias. Of the 84 patients, 64 (76.2%) were female and 
the rest were male. Of all patients with positive urine, 31 cases 
(36.9%) had symptoms of pyelonephritis, 25 patients (29.8%) 
had symptoms of cystitis and 28 patients (33.3%) had 
symptoms of urinary tract inflammation. The demographic 
characteristics of patients are shown in table 1. In antibiogram 
for positive urine samples, 21 pieces (25%) were resistant to 
ciprofloxacin and 46 pieces (43%) were resistant to nalidixic 
acid which significantly reduced resistance to ciprofloxacin 
(P=0.005). The drug resistance levels of ciprofloxacin and 
Nalidixic acid in terms of the location of the involvement are 
shown in table 2. As can be seen there was no significant 
difference between the two antibiotics in place of clinical 
symptoms and drug resistance (P=0.085). So there was no 
significant difference between the two MIC and MBC in place 
of clinical symptoms and drug resistance (P=0.069). 
Distribution of MIC and MBC ciprofloxacin and nalidixic Acid 
are shown in Chart 1. 
Table 1. Characteristics of the population with positive urine culture 
Characteristic 
(N=84) 
Variables 
Number (Percent) / Mean 
Sex  
 Male 
 Female 
 
20(23.8) 
64(76.2) 
Mean Age (years) 38.4±14.2 
Age groups 
 <20 years 
 20-40 years 
 41-60 years 
 >60 years 
 
7(8.3) 
46(54.7) 
23(27.4) 
8(9.5) 
Mean BMI (kg/m2) 24.35±4.17 
Symptomatic urinary tract area 
 Upper (Pyelonephritis) 
 Lower (Cystitis and Urethritis) 
 
31(36.9) 
53(63.1) 
Marital status 
 Single 
 Married 
 
23(27.3) 
61(72.7) 
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Discussion 
According to the results of this study, 84 urine samples 
from patients with urinary tract infection with various 
microorganism, especially E. coli, among 21 patients (25%) 
with UTI, were resistant to ciprofloxacin antibiotics, and for 
nalidixic acid antibiotics, 46 patients (54.7%) were also 
resistant to nalidixic acid antibiotics. In the Swami study, E. 
coli resistance to ciprofloxacin antibiotic was 2.7% and the 
resistance to antibiotic nalidixic acid was 16.22%.23 This 
suggests a greater effect of ciprofloxacin antibiotic on E. coli 
from urine specimens and while nalidixic acid antibiotics are 
rapidly resistant, this is also mentioned in Hsu and Costelloe 
studies,24-25 which emphasizes the use of ciprofloxacin. In this 
study, MIC was the antibiotic ciprofloxacin was found to be 
less resistant to the nalidixic acid. According to the findings of 
this study, in 57.1% of cases, patients with urethral duct, 28.6% 
of patients with pyelonephritis and 14.3% of them had cystitis 
was observed resistance to ciprofloxacin, in the case of 
nalidixic acid, this level of resistance was respectively 28 
(60.9%), 11 (25.6%) and 7 (15.2%) which is consistent with 
Freeman's research findings.26 In addition 53.48% of these 
patients had MIC resistant to ciprofloxacin and 61.53% of these 
patients had nalidixic acid -resistant MIC which is consistent 
with Sun's research findings but contradicts Adam's results, 
perhaps because of the size of the sample examined in the two 
studies above.27-28 On the other hand, 34.8% of these patients 
had MBC resistant to ciprofloxacin and 55.6% of these patients 
had nalidixic acid -resistant MBC which is similar to 
Cornaglia's research results.29 Regarding these findings, there 
was a significant relationship between the antibiogram of 
ciprofloxacin and nalidixic acid, but no significant relationship 
was found between the place of infection (the kidney, bladder 
and urethra). This finding suggests that the location of the 
infection does not play an important role in antibiotic selection. 
Also, in the MIC, there was no significant relationship between 
the two antibiotics that was found with the results of studies 
and consistency.  
Antimicrobial resistance poses grave concerns for 
antimicrobial effectiveness in treating infections such as UTI. 
This study demonstrates the increasing resistance of urinary E. 
coli to commonly prescribed antimicrobials. The antibiogram 
and MIC of the two antibiotics ciprofloxacin and nalidixic acid 
showed that nalidixic acid resistance was higher than 
ciprofloxacin and this should be considered in prescribing for 
the needy and ciprofloxacin can be used to treat urethritis, 
cystitis, and pyelonephritis. 
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